Glucose Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Glucose Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $19.2K | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | $397 | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | ($20.7K) | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | ($2.1K) | Mar 30, 2015 |
| FY2012 | Dec 31, 2012 | ($3.6K) | May 5, 2014 |
| FY2011 | Dec 31, 2010 | ($947) | May 31, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | ($410.4K) | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | ($266.1K) | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | ($669.4K) | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | ($1.46M) | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | ($399.1K) | Jun 25, 2014 |
| FY2012 | Dec 31, 2011 | ($899.2K) | May 5, 2014 |
| FY2011 | Dec 31, 2010 | ($632.7K) | May 31, 2012 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | ($86.6K) | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | ($156.2K) | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | ($545.2K) | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | ($1.27M) | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | ($361.4K) | Jun 25, 2014 |
| FY2012 | Dec 31, 2011 | ($888.8K) | May 5, 2014 |
| FY2011 | Dec 31, 2010 | ($614.8K) | May 31, 2012 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $48 | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $4.0K | Apr 14, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | ($39.3K) | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | ($115.8K) | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | ($135.4K) | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | ($132.0K) | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | ($83.7K) | Jun 25, 2014 |
| FY2012 | Dec 31, 2011 | ($23.3K) | May 5, 2014 |
| FY2011 | Dec 31, 2010 | ($109.6K) | May 31, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $33.1K | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | $15.4K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $44.0K | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $25.6K | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $207.7K | Jun 25, 2014 |
| FY2012 | Dec 31, 2011 | $233.7K | May 5, 2014 |
| FY2011 | Dec 31, 2010 | $87.8K | May 31, 2012 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $528.6K | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | $403.2K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $324.6K | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $223.3K | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $185.5K | Jun 25, 2014 |
| FY2012 | Dec 31, 2011 | $419.7K | May 5, 2014 |
| FY2011 | Dec 31, 2010 | $682.4K | May 31, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | ($495.4K) | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | ($387.8K) | Mar 29, 2017 |
| FY2016 | Dec 31, 2014 | ($280.6K) | Mar 29, 2017 |
| FY2015 | Dec 31, 2013 | ($197.8K) | Apr 14, 2016 |
| FY2014 | Dec 31, 2012 | $22.2K | Mar 30, 2015 |
| FY2013 | Dec 31, 2011 | ($186.0K) | Jun 25, 2014 |
| FY2013 | Sep 30, 2011 | ($310.1K) | Jun 25, 2014 |
| FY2012 | Dec 31, 2010 | ($594.6K) | May 5, 2014 |
| FY2011 | Dec 31, 2009 | ($301.1K) | May 31, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | ($6.25M) | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | ($5.84M) | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | ($5.57M) | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | ($4.90M) | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | ($2.87M) | Jun 25, 2014 |
| FY2012 | Dec 31, 2011 | ($2.87M) | May 5, 2014 |
| FY2011 | Dec 31, 2010 | ($2.14M) | May 31, 2012 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $20.5K | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | $2.1K | Mar 29, 2017 |
| FY2016 | Dec 31, 2014 | $4.9K | Mar 29, 2017 |
| FY2015 | Dec 31, 2013 | $711 | Apr 14, 2016 |
| FY2014 | Dec 31, 2012 | $1.1K | Mar 30, 2015 |
| FY2013 | Dec 31, 2011 | $82 | Jun 25, 2014 |
| FY2013 | Sep 30, 2011 | $3.9K | Jun 25, 2014 |
| FY2012 | Dec 31, 2010 | $33 | May 5, 2014 |
| FY2011 | Dec 31, 2009 | $4 | May 31, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | 0 | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | (4) | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Jun 25, 2014 |
| FY2012 | Dec 31, 2011 | 0 | May 5, 2014 |
| FY2011 | Dec 31, 2010 | 0 | May 31, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | 3.31M | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | 2.45M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | 1.31M | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | 377,456 | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | 10.11M | Jun 25, 2014 |
| FY2012 | Dec 31, 2011 | 65.44M | May 5, 2014 |
| FY2011 | Dec 31, 2010 | 19.73M | May 31, 2012 |